Vida Ventures
Venture capitalLos Angeles · Pre-Seed–Late Stage · 35 people tracked
Also known as VIDA VENTURES ADVISORS, LLC · VIDA VENTURES MANAGEMENT CO. LLC · Vida Wealth Partners, Inc.
Investment thesis
Vida Ventures invests in biomedical innovation with the goal of advancing breakthrough science into therapies that make a meaningful difference for patients. The firm emphasizes company creation and value realization in the therapeutics space, backing novel drug programs across areas such as genetic medicines and immunology. Its approach is grounded in core values including patient focus, integrity, entrepreneurship, boldness, humility, collaboration, and flexibility, reflecting a partnership-driven model that supports founders in turning cutting-edge science into clinical-stage medicines.
Source: firm website, verified Aug 25, 2026.
Team · 35 people
from the firm's website & public directories
Founder mafia
4 people who came through Vida Ventures went on to found or lead other companies.
What they invest in
from 40 of 51 portfolio companiesBiotech ×38Healthtech ×16Medical Devices ×15Deep Tech ×8AI & Machine Learning ×7Digital Health ×5Consumer ×1Direct to Consumer ×1
HQs:United States×36Denmark×1
Who they back
founder profiles across 14 portfolio companiesFounding team size:solo founder×82 founders×43 founders×14+ founders×1
Investments · 51 tracked
founders shown can be your intro pathBy year:2026 · 22025 · 22024 · 42023 · 22022 · 22021 · 12020 · 22019 · 12018 · 22017 · 422 dated
Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors.
BiotechHealthtechMedical DevicesBoston, US
Todd Foley(Co-founder and Chairman)inPatrick Baeuerle(Co-founder & Advisor)inShulamit Ron-Bigger(Executive Officer)
BoardOleg Nodelman(Director)inAndrew Levin(Director)
Board seatHelen S. Kim· per SEC Form D
Co-investorsAndreessen HorowitzEcoR1 CapitalMPM BioImpactMRL Ventures FundRA CapitalTCG Crossover+2 more
Therapeutic company focused on validated targets for treating neurological and psychiatric disorders.
BiotechCambridge, US
Kiran Reddy(Executive Officer, Director)
BoardNicholas G. Galakatos(Director)
Board seatStefan Vitorovic· per SEC Form D · $10M raise · filed Jun 2019
Co-investorsOCV PartnersClarus
Allogene Therapeutics develops allogeneic CAR T cell therapies (AlloCAR T) for blood cancers, solid tumors, and autoimmune diseases, using off-the-shelf manufactured cell products rather than patient-derived autologous approaches.
BiotechHealthtechMedical DevicesSouth San Francisco, US
ROBERT ABRAHAM(Director)JOSHUA A. KAZAM(Executive Officer, Director)DAVID M. TANEN(Executive Officer)FRANZ HUMER(Director)JOHN DEYOUNG(Director)
BoardOWEN WITTE(Director)
Co-investorsAvoro Capital AdvisorsForesite CapitalTPG
Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.
BiotechHealthtech
Lyn Baranowski(CEO)in
Co-investorsAndera PartnersCatalio Capital Management, LPF-Prime CapitalInVivium CapitalNorwest Venture PartnersRiverVest Venture Partners+7 more
Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform.
BiotechMedical DevicesWaltham, US
Romesh Subramanian, Ph.D.(Executive Officer)Richard Scalzo(Executive Officer)Joshua Brumm(Executive Officer, Director)Jonathan McNeill, M.D.(Executive Officer)Oxana Beskrovnaya, Ph.D.(Executive Officer)
BoardLawrence Klein, Ph.D.(Director)
Co-investorsAtlas VentureMPM BioImpactForbionHercules Capital, Inc.
A clinical-stage biopharmaceutical company developing small molecule therapies for schizophrenia, bipolar depression, and other neuropsychiatric disorders.
BiotechHealthtechNew York, US
Zachary Prensky(Executive Officer, Director)Lauren Stipp(Executive Officer)Mark Panoff(Executive Officer)
BoardEdmund Sullivan(Director)Vincent Grattan(Director)
Co-investorsPontifax Venture CapitalTarnagulla VenturesTCG Crossover
Adcendo develops antibody-drug conjugates (ADCs) engineered to treat cancers with high unmet medical needs.
BiotechDigital HealthMedical Devices
Co-investorsYsios CapitalJeito Capital
Adcendo develops antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need.
BiotechMedical Devices
Co-investorsHealthCapJeito CapitalNovo HoldingsOrbiMedPontifax Venture CapitalRA Capital+2 more
Antares Therapeutics discovers and develops precision medicines, with a focus on small molecule therapies targeting previously undruggable oncology targets and other serious diseases.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Adam Friedman(Chief Executive Officer)inAndrew Fedder(Executive Officer, Director)inBrian Piper(Executive Officer, Director)
Co-investorsAtlas VentureLightspeed Venture PartnersOmega FundsTenmileAbingworthBiotechnology Value Fund
InduPro develops next-generation protein therapeutics by leveraging inherent and induced proximity to modulate disease biology, with a focus on ADCs and T-cell engagers.
BiotechDeep TechMedical DevicesSeattle, US
K. Chris Garcia(Scientific Founder)Prakash Raman(CEO)Amanda J. Redig(Chief Medical Officer)Scott Lesley(President & CSO)Pamela Holland(SVP of Biology)Sally Johnson(Chief People Officer)
Co-investorsMRL Ventures FundThe Column Group
SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way.
BiotechDeep TechHealthtechSouth San Francisco, US
Kenneth Greenberg(Co-Founder, President & CEO)in
Co-investorsLeaps by BayerFoothill VenturesIllumina VenturesMedical Excellence CapitalVivo CapitalARCH Venture Partners+1 more
A2 Bio develops precision CAR T-cell therapies using its Tmod cell engineering platform, supporting both autologous and allogeneic applications.
BiotechHealthtechAgoura Hills, US
C. Alexander Kamb(Director)Scott Foraker(Executive Officer, Director)Madhavan Balachandran(Director)Michael Gallo(Director)
BoardSrini Akkaraju(Director)inDavid Goeddel(Director)
Board seatHelen S. Kim· per SEC Form D
Co-investorsNextech InvestSamsara BioCapitalThe Column Group
New York, US
Jesse Horwitz(Executive Officer, Director)Benjamin Cogan(Executive Officer, Director)Eric Osman(Executive Officer, Director)
Board seatJoshua Kazam· per SEC Form D · $500K raise · filed Jan 2018
ByHeart is an infant formula company navigating an FDA return-to-market process following a product outbreak investigation.
ConsumerDirect to ConsumerFoodTechHealthtechNew York, US
Mia B. Funt(Executive Officer, Director)Ron Belldegrun(Executive Officer, Director, Promoter)Mia Funt(Founder)inGeorg Krause-Vilmar(Executive Officer)Niall Mullane(Executive Officer)
BoardAmy Schulman(Director)in
Board seatArie BelldegrunJoshua Kazam· per SEC Form D · $95.5M raise · filed May 2026
Co-investorsEvolution VC PartnersOCV PartnersPolaris PartnersRed Sea Ventures
Iconovir is a biotechnology company focused on developing cancer treatments, with a stated mission to cure cancer and restore life to patients.
BiotechHealthtechNew York, US
Sean Algeo(Executive Officer, Promoter)Mark A. McCamish(Executive Officer, Director)David M. Tanen(Executive Officer, Promoter)
BoardDavid Chang(Director, Promoter)Helen Kim(Director)Jakob Loven(Director)in
Board seatHelen S. KimJoshua KazamArie Belldegrun· per SEC Form D
Co-investorsGV (Google Ventures)Nextech InvestWellington Management
BiotechNew York, US
Norbert Bischofberger, Ph.D.(Executive Officer, Director)Christopher Wilfong(Executive Officer)
BoardRebecka Belldegrun, M.D.(Director)Otello Stampacchia, Ph.D.(Director)David M. Tanen(Executive Officer, Director, Promoter)Arie S. Belldegrun, M.D.(Director)
Board seatJoshua Kazam· per SEC Form D
Co-investorsEcoR1 CapitalGV (Google Ventures)Nextech Invest
HealthtechNew York, US
Ron Belldegrun(Executive Officer, Director)Georg Krause-Vilmar(Executive Officer)Mia B. Funt(Executive Officer, Director)Devon Kuehn(Executive Officer)Niall Mullane(Executive Officer)Neil Betteridge(Executive Officer)
Board seatArie BelldegrunJoshua Kazam· per SEC Form D · $20.3M raise · filed Jul 2026
Co-investorsOCV Partners
Clinical-stage biotech developing neoantigen-targeted T cell receptor (TCR) therapies for cancer; acquired by AstraZeneca.
BiotechNew York, US
Carsten Linnemann, PhD(Executive Officer, Director, Promoter)Antonius N.M. Schumacher(Director)Fei Chen(Director)
BoardDavid M. Tanen(Director, Promoter)Helen Kim(Director)
Board seatRajul Jain· per SEC Form D
Co-investorsEcoR1 CapitalJeito CapitalTPG
ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs.
AI & Machine LearningBiotechMedical DevicesMenlo Park, US
Dr. Daniel J. Siegwart
Board seatHelen S. Kim· per SEC Form D
Co-investorsAju IB Invesment CorporationEcoR1 CapitalEvolution VC PartnersMPM BioImpactOrbiMedOUP (Osage University Partners)+6 more
New York, US
William Herlands(Executive Officer, Director)Jesse Horwitz(Executive Officer, Director)Drew Tarlow(Director)Benjamin Cogan(Executive Officer, Director)
BoardRick Heitzmann(Director)
Board seatJoshua Kazam· per SEC Form D · $500K raise · filed Jan 2018
Tectonic is a clinical-stage biotechnology company developing therapeutic proteins and antibodies that target G-Protein Coupled Receptors (GPCRs) using a proprietary platform called GEODe™.
AI & Machine LearningBiotechMedical DevicesWatertown, US
Timothy A. Springer(Co-Founder)Andrew C. KruseTimothy Springer(Director)Andrew Kruse(Director)Alise Reicin(Executive Officer, Director)Daniel Lochner(Executive Officer)
Board seatStefan Vitorovic· per SEC Form D
Co-investorsEcoR1 CapitalAlly Bridge GroupClarusPolaris PartnersSoleus Capital
New York, US
Christopher Wilfong(Executive Officer)Alex Kaufman(Executive Officer, Director)
BoardRon Belldegrun(Director)Joshua A. Kazam(Director, Promoter)David M. Tanen(Director, Promoter)Gregory F. Kiernan(Director, Promoter)
Board seatJoshua Kazam· per SEC Form D · $6.6M raise · filed Feb 2017
An R&D-driven biopharmaceutical company that uses AI to develop breakthrough medicines and vaccines focused on immune system disorders across five therapeutic areas.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Ivana Magovcevic-Liebisch(Executive Officer, Director)Christopher Verni(Executive Officer)Mary Thistle(Director)Evan Thackaberry(Executive Officer)Suzanne Bruhn(Director)Gerhard Koenig(Director)
Board seatStefan Vitorovic· per SEC Form D
Co-investorsAtlas VentureLightstone VenturesHatteras Venture PartnersLongwood Fund
New York, US
Jesse Horwitz(Executive Officer, Director)Benjamin Cogan(Executive Officer, Director)
BoardLeonard Potter(Director)Rick Heitzmann(Director)Kejia Sun(Director)
Board seatJoshua Kazam· per SEC Form D · $16.5M raise · filed Mar 2017
Volastra Therapeutics is a drug discovery and development company working on novel cancer therapies.
BiotechHealthtechNew York, US
Samuel Bakhoum(Co-Founder & Chief Scientific Officer)Lewis Cantley(Founder and Chair of Scientific Advisory Committee)Olivier Elemento(Founder and Scientific Advisor)David P. Southwell(Chief Executive Officer)Sandra Peterson(Director)David Southwell(Executive Officer, Director)
Board seatStefan Vitorovic· per SEC Form D
Co-investorsDroia VenturesARCH Venture PartnersB Capital GroupB4 Capital
BiotechWatertown, US
Kathy Bergsteinsson(Executive Officer)Kathy Yi(Executive Officer)Joseph Knowles(Executive Officer, Director)
BoardLucio Iannone(Director)Arjun Goyal(Director)Jill DeSimone(Director)
Co-investorsLeaps by Bayer
Alterome is a clinical-stage precision oncology company developing small-molecule, alteration-specific cancer therapies, with two internally discovered drug candidates in the clinic.
AI & Machine LearningBiotechDeep TechSan Diego, US
Eric A. Murphy(Executive Officer, Director, Promoter)Ryan B. Corcoran(Director, Promoter)
BoardThilo Schroeder(Director)inCarl Gordon(Director)inArjun Goyal(Director)in
Co-investorsCanaan PartnersNextech InvestOrbiMedDigitalis VenturesNVIDIA
AskBio is a gene therapy company developing adeno-associated virus (AAV)-based genetic medicines for rare and other diseases, with clinical programs such as AB-1009 for late-onset Pompe disease.
BiotechDeep TechHealthtechDurham, US
Co-investorsTPGColumbus Venture Partners
Attovia is a biotechnology company focused on drug development and clinical strategy, aiming to bring treatments to patients where none exist and create next-generation therapeutic options.
BiotechDigital Health
Zaneta Odrowaz(Founder)in
Co-investorsEcoR1 CapitalFrazier Life SciencesIllumina VenturesNextech InvestSanofi VenturesGoldman Sachs
CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.
BiotechHealthtechSan Diego, US
Ken Song(Chairman, President and CEO)Kenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)Bernie Huyghe, Ph.D.(Executive Officer)
BoardJeffrey Tong, Ph.D.(Director)
Co-investorsForesite CapitalOrbiMedSamsara BioCapitalTCG CrossoverThird Rock VenturesvenBio Partners
AbbVie is a biopharmaceutical company that discovers and delivers medicines for immune-mediated diseases and other therapeutic areas globally.
BiotechHealthtechMedical DevicesSan Diego, US
Adrian Bot(Executive Officer)Laura Shawver(Executive Officer, Director)Ramin Farzaneh-Far(Executive Officer)Justin Thacker(Executive Officer)Karen Smith(Director)Fabio Pucci(Director)
Co-investorsPfizer Venture InvestmentsRA CapitalSofinnova Ventures
Centessa is a biopharmaceutical company developing an Orexin Receptor 2 Agonist program aimed at treating sleep-wake, neurological, neurodegenerative, and neuropsychiatric disorders.
BiotechHealthtech
Co-investorsAdvent Life SciencesEcoR1 CapitalForesite CapitalMedicxiOberland CapitalScion Life Sciences+1 more
BiotechMedical DevicesNew Haven, US
Scott Phillips(Executive Officer)
BoardTim Shannon(Manager)inLiam Ratcliffe(Manager)
Co-investorsAccess BiotechnologyCanaan PartnersConnecticut InnovationsFrazier Life SciencesRA CapitalTaiho Ventures, LLC
Clinical-stage genetic medicines company using human-derived AAV vectors and nuclease-free gene editing for rare diseases.
BiotechBedford, US
Siyamak Rasty(Executive Officer)Albert Seymour(Executive Officer)
BoardSteven Gillis(Director)Arthur Tzianabos(Executive Officer, Director)Kush Parmar(Director)inRichard Gregory(Director)
Co-investors5AM VenturesARCH Venture PartnersOUP (Osage University Partners)AlexandriaDeerfield Management CompanyHBM Healthcare Investments+4 more
Kyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset.
Biotech
Co-investorsWestlake Village BioPartners
Peloton Therapeutics is a clinical-stage pharmaceutical company developing first-in-class small molecule medicines targeting HIF-2α for cancer and other life-threatening conditions, with initial focus on kidney cancer and VHL disease.
BiotechDigital HealthMedical Devices
Co-investorsNextech InvestThe Column Group
Poplar Therapeutics is a company whose website provides informational content; based on its name it operates in therapeutics/biotech, though the available page (a privacy policy) does not describe its specific products or focus.
Biotech
Precision Medicine Group provides biomarker-driven research and development services and commercialization support for pharmaceutical and life science companies across drug development, manufacturing, and market access.
BiotechHealthtechMedical Devices
Co-investorsOak HC/FTOak Investment Partners
Protego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones.
AI & Machine LearningBiotechDeep TechDigital HealthSan Diego, US
Co-investorsDroia VenturesNovartis Venture FundDigitalis VenturesForbionLightspeed Venture PartnersMPM BioImpact+1 more
Co-investorsMPM BioImpact
Quanta is a biotech company developing orally bioavailable, CNS-penetrant small-molecule KRAS inhibitors targeting RAS-driven cancers such as pancreatic, colorectal, lung, and endometrial cancers.
BiotechDeep TechHealthtechSouth San Francisco, US
Cameron Pitt(Executive Officer, Director)Ying Huang(Director)Derek Metzger(Executive Officer)
BoardMaha Katabi(Director)Perry Nisen(Executive Officer, Director)Maria Fardis(Director)
Co-investorsLongitude CapitalSofinnova VenturesFrazier Life Sciences
BiotechBoston, US
Adam Friedman(Executive Officer, Director)Gary Glick(Executive Officer, Director)Andrew Fedder(Executive Officer)Darrin Stuart(Executive Officer)Erica Jackson(Executive Officer)Amanda Valentino(Executive Officer)
Co-investorsAtlas VentureAvoro Capital AdvisorsEcoR1 CapitalFrazier Life SciencesNextech InvestLightspeed Venture Partners+2 more
SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound enhancing agents) to deliver genetic payloads to targeted sites in a redosable manner.
BiotechDeep TechDigital Health
Kenneth Greenberg(Founder)in
Co-investorsARCH Venture PartnersLeaps by BayerSymBiosisUCB VenturesVivo Capital
Soufflé Therapeutics develops nucleic acid medicines that precisely target and deliver genetic therapeutics to specific cell types to treat disease.
AI & Machine LearningBiotechDeep Tech
Victor Kotelianski(Founder)Daniel Anderson(Founder)Robert Langer(Founder)Marino Zerial(Founder)Brad Pentelute(Founder)Amir Nashat(Chief Executive Officer)
Co-investorsLeaps by BayerBessemer Venture PartnersSafar Partners
Third Arc Bio develops breakthrough treatments in oncology and immunology through advanced biologics engineering.
BiotechMedical DevicesLower Gwynedd, US
Joseph Erhardt(Executive Officer)Peter Lebowitz(Executive Officer, Director)
BoardArjun Goyal(Director)inOtello Stampacchia(Director)inFrancesco Draetta(Director)in
Co-investorsAndreessen Horowitzabrdn plcBiotechnology Value FundForesite CapitalHillhouse InvestmentOmega Funds+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 6
IPOs and acquisitions across the tracked portfolioAktis OncologyNASDAQ: AKTSPraxis Precision MedicinesNASDAQ: PRAXAllogene TherapeuticsNASDAQ: ALLOAvalyn Pharma IncNASDAQ: AVLNDyne TherapeuticsNASDAQ: DYNLB PharmaceuticalsNASDAQ: LBRX
Portfolio news
latest coverage across their companiesPraxis Precision Medicines · investing.com · Aug 17, 2026
SonoThera · fiercebiotech.com · Aug 12, 2026
MeridianMade, Inc. · alleywatch.com · Jul 27, 2026
Attovia Therapeutics · medicaldialogues.in · Jul 19, 2026
SonoThera · statnews.com · Jul 17, 2026
Allogene Therapeutics · investing.com · Jul 15, 2026
Alterome Therapeutics, Inc. · geekwire.com · Jul 13, 2026
Fund performance · per public LP disclosures
as of Jun 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Vida Ventures IILPs: The Regents of the University of California | 2019 | — | 2.1% | 1.08x | 0.63x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Public market activity · per SEC filings
what is this? ⓘ1 insider ownership filing (Forms 3/4/5)
at LB PHARMACEUTICALS INC (LBRX)
Files 13F institutional holdings reports · latest Nov 2025
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- How many investments has Vida Ventures made?
- Vida Ventures has 39 tracked investments, including 1 dated in the last 24 months.
- What stage does Vida Ventures invest at?
- Vida Ventures invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does Vida Ventures focus on?
- Vida Ventures focuses on Biotech, Deep Tech, Healthtech, Medical Devices.
- Where is Vida Ventures located?
- Vida Ventures is headquartered in Los Angeles, US.
- Does Vida Ventures lead rounds?
- Vida Ventures typically participates in rounds rather than leading them.
- Who does Vida Ventures co-invest with?
- Vida Ventures most often shares deals with EcoR1 Capital, Nextech Invest, Atlas Venture, among 78 tracked co-investors.
Co-investors · 20
Nextech Invest is a Zurich-based investment firm focused on emerging biotechnology companies, backing transformative cancer medicines and precision medicine advances worldwide.
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.
The Column Group (TCG) is a venture capital firm focused on building and backing biotechnology companies, applying an edge-to-edge investment model centered on company formation with capacity for long-term private and public capital support.
Omega Funds invests in venture capital and growth equity opportunities across the life sciences sector.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.
Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.
Vivo Capital is a global healthcare-focused investment firm operating a multi-strategy platform spanning venture capital, private equity, and public equity. It aims to expand healthcare access and drive innovation through its 'Ecosystem Strategy.'
Pontifax is an investment firm focused on life sciences and healthcare technologies, backing companies across all development stages from early research to clinical-stage growth.
▶8 more co-investors
Ysios CapitalMedical Excellence CapitalHealthCapNew Enterprise Associates (NEA)General AtlanticXtripe AngelsJohnson & Johnson Innovation – JJDCVertex Ventures HC
Firms observed investing alongside Vida Ventures, from public investor directories. Shared companies are the overlap with Vida Ventures's recorded portfolio.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
Pontifax is an investment firm focused on life sciences and healthcare technologies, backing companies across all development stages from early research to clinical-stage growth.
OUP (Osage University Partners) is a venture firm that invests in science-driven startups commercializing deep technology innovations emerging from university and breakthrough research.
LIFTT is a venture capital holding company focused on deep tech technologies, using an operational, multi-vertical approach aimed at generating impact. It works to transform scientific research into high-impact companies, accelerating the path from lab to market.